Since the introduction of a new listing regime on 30 April 2018 that enables the listing of pre-revenue Biotech Companies on the Main Board of the Hong Kong Stock Exchange (the “Exchange”), a total of 16 of these listings...more
In response to the outbreak of a pneumonia-like disease caused by coronavirus (COVID-19), Chinese regulatory authorities adopted a few emergency measures under certain “Special Review and Approval Procedures” to fast-track...more
3/9/2020
/ China ,
Coronavirus/COVID-19 ,
Drug Approvals ,
Health and Safety ,
Infectious Diseases ,
Investigational New Drug Application (IND) ,
Pharmaceutical Industry ,
Prescription Drugs ,
Proposed Amendments ,
Public Health ,
Vaccinations